Upgrade to SI Premium - Free Trial

Larimar Therapeutics (LRMR)

3.83 0.00 (0.00%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (11/5/26)

Latest Headlines

Larimar Therapeutics, Inc. (LRMR) Tops Q2 EPS by 8c August 4, 2026 7:24 AM - StreetInsider Form 10-Q Larimar Therapeutics, For: Jun 30 August 4, 2026 7:12 AM - SEC Filing Form 8-K Larimar Therapeutics, For: Aug 04 August 4, 2026 7:03 AM - SEC Filing Larimar Therapeutics Reports Second Quarter 2026 Financial and Business Update August 4, 2026 7:00 AM - Globe NewsWire Form 4 Larimar Therapeutics, For: Jul 06 Filed by: Hamilton Thomas Edward July 8, 2026 4:05 PM - SEC Filing Larimar Therapeutics (LRMR) Reiterated at Market Outperform by Citizens July 7, 2026 5:21 AM - StreetInsider H.C. Wainwright Assumes Larimar Therapeutics (LRMR) at Buy July 2, 2026 6:05 AM - StreetInsider Larimar Therapeutics (LRMR) PT Lowered to $5 at Baird June 30, 2026 6:54 AM - StreetInsider Form 8-K Larimar Therapeutics, For: Jun 29 June 29, 2026 6:34 AM - SEC Filing Larimar files first BLA module for Friedreich's ataxia drug June 29, 2026 6:30 AM - StreetInsider Larimar Therapeutics Reports Positive Open Label Data and Submission of First Module of Rolling BLA for Accelerated Approval of Nomlabofusp for Friedreich’s Ataxia June 29, 2026 6:30 AM - Globe NewsWire Larimar Therapeutics to host investor event on June 29 June 26, 2026 4:05 PM - StreetInsider Larimar Therapeutics Announces Investor Event on the Nomlabofusp Program for Friedreich’s Ataxia June 26, 2026 4:05 PM - Globe NewsWire Full Article List